Jiangsu Recbio Technology Co Ltd
Company Profile
Business description
Jiangsu Recbio Technology Co Ltd is a vaccine company focused on the research, development, and commercialization of vaccines, with a high-value vaccine portfolio driven by in-house technologies. It has built three vaccine technology platforms: novel adjuvants, protein engineering, and immune evaluation. The company's portfolio currently consists of various vaccines, covering diseases such as cervical cancer, herpes zoster, and respiratory syncytial virus. It has two core strategic products, namely REC610, a novel adjuvanted recombinant shingles vaccine, which is currently in the stage of marketing application in China, and REC603, a recombinant HPV 9-valent vaccine under phase three clinical trial.
Contact
No. 888 Yaocheng Avenue
Medical High-tech District
Jiangsu Province
Taizhou
CHNT: +86 52386818860
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
466
Stocks News & Analysis
stocks
Older cohorts the budget losers, not necessarily the ASX listed insurers
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,717.00 | 82.40 | -0.94% |
| CAC 40 | 7,982.00 | 0.24 | 0.00% |
| DAX 40 | 24,387.51 | 13.14 | -0.05% |
| Dow JONES (US) | 49,363.88 | 322.24 | -0.65% |
| FTSE 100 | 10,293.66 | 36.89 | -0.36% |
| HKSE | 25,643.59 | 154.26 | -0.60% |
| NASDAQ | 25,870.71 | 220.02 | -0.84% |
| Nikkei 225 | 59,804.41 | 746.18 | -1.23% |
| NZX 50 Index | 12,761.03 | 213.29 | -1.64% |
| S&P 500 | 7,353.61 | 49.44 | -0.67% |
| S&P/ASX 200 | 8,496.60 | 76.50 | -0.89% |
| SSE Composite Index | 4,162.18 | 7.35 | -0.18% |